NSE filing, NSE: GLENMARK. Summary written from the filing by ALFA Finder's alert engine.
Glenmark Pharmaceuticals Ltd: key numbers
- Share price
- ₹2,481.80
- Market cap
- ₹70,043 Cr
- Revenue (annual)
- ₹16,983 Cr
- Net profit (annual)
- ₹1,362 Cr
- P/E (TTM)
- 39.0×Sector 37.9×
- Promoter holding
- 46.65%+0.00% QoQ
- FII holding
- 21.51%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Glenmark Pharmaceuticals Ltd
All →Glenmark Pharmaceuticals Investor Presentation: Key Takeaways
Q2 FY27 consolidated revenue Rs 42,473 Mn, down 29.8% YoY on a reported basis. EBITDA Rs 8,638 Mn (20.3% margin); Adj PAT Rs 4,852 Mn (11.4% margin). North America headline is flattered by ISB 2001 licensing income.
Glenmark Pharmaceuticals Q2 FY27 Results: Net Profit ₹263.8 Cr, Down 56.8% YoY
Glenmark Pharmaceuticals Ltd reported revenue from operations of ₹4,247 Cr (-29.8% YoY) and net profit of ₹263.8 Cr (-56.8% YoY) for Q2 FY27.
- Key figure
- Net profit ₹263.8 Cr · -56.8% YoY
Glenmark Pharmaceuticals Other Announcement
Glenmark's partner IGI will present updated Phase 1 clinical data for ISB 2001 (ABBV-2001) in relapsed/refractory multiple myeloma at the 68th ASH Annual Meeting. The presentation is scheduled for December 12, 2026.
Glenmark Pharmaceuticals Board Meeting Date
Glenmark Pharmaceuticals notified BSE of a board meeting on 05 Nov 2026 to consider unaudited Q2 FY27 results. No financial figures are disclosed in this advance intimation.
Glenmark Pharmaceuticals Other Announcement
Glenmark Pharmaceuticals has filed its quarterly shareholding pattern for the period ended September 30, 2026, as required under SEBI Regulation 31(1)(b).
Glenmark Pharmaceuticals Product Launch
Glenmark Pharmaceuticals launched Adapalene Gel USP, 0.1% (OTC) in new pump packs in the USA, expanding its dermatology portfolio.
Other results update announcements
All →Aditya Infotech Results Update
Aditya Infotech reports Q2 FY27 revenue of ₹1,746 Crore, up 89.9% YoY, with EBITDA rising 176.7%. Management raised FY27 revenue guidance to ₹6,500–6,800 Crore.
Rikhav Securities Results Update
Rikhav Securities reported H1 FY27 total income of ₹869.07 Cr and PAT of ₹13.60 Cr. The earnings press release also covers EBITDA and EPS.
IRIS RegTech Solutions Results Update
IRIS RegTech reported Q2 FY27 press release highlights: revenue up 35% YoY, EBITDA INR 4.1 crore, and RegTech ARR up 42% YTD. No full SEBI results statement is attached, only a press release.
The Ramco Cements Results Update
Ramco Cements issued a press release on standalone unaudited Q2FY27 results, citing 4.74 million tons sales volume and Rs.2,466 crore net revenue. EBITDA fell 16% to Rs.331 crore on higher fuel and packing costs.
Scan Steels Results Update
Scan Steels reported H1 FY27 revenue of Rs.4,282 Mn, up 17% YoY, and PAT of Rs.275 Mn, up 181%. Q2 EBITDA rose 143% YoY to Rs.138 Mn.
Sinclairs Hotels Results Update
Sinclairs Hotels reported half-year profit growth in its unaudited results for the period ended September 2026. Second-quarter results stayed loss-making despite positive EBITDA.